148 related articles for article (PubMed ID: 24114765)
21. Enhancement of cisplatin sensitivity in lung cancer xenografts by liposome-mediated delivery of the plasmid expressing small hairpin RNA targeting Survivin.
Tian H; Liu S; Zhang J; Zhang S; Cheng L; Li C; Zhang X; Dail L; Fan P; Dai L; Yan N; Wang R; Wei Y; Deng H
J Biomed Nanotechnol; 2012 Aug; 8(4):633-41. PubMed ID: 22852473
[TBL] [Abstract][Full Text] [Related]
22. Enhanced Anti-Tumor Efficacy of Lipid-Modified Platinum Derivatives in Combination with Survivin Silencing siRNA in Resistant Non-Small Cell Lung Cancer.
Mattheolabakis G; Ling D; Ahmad G; Amiji M
Pharm Res; 2016 Dec; 33(12):2943-2953. PubMed ID: 27528390
[TBL] [Abstract][Full Text] [Related]
23. Metabolomic Identification of Anticancer Metabolites of Australian Propolis and Proteomic Elucidation of Its Synergistic Mechanisms with Doxorubicin in the MCF7 Cells.
Alsherbiny MA; Bhuyan DJ; Radwan I; Chang D; Li CG
Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360606
[TBL] [Abstract][Full Text] [Related]
24. A Light-Driven Therapy of Pancreatic Adenocarcinoma Using Gold Nanorods-Based Nanocarriers for Co-Delivery of Doxorubicin and siRNA.
Yin F; Yang C; Wang Q; Zeng S; Hu R; Lin G; Tian J; Hu S; Lan RF; Yoon HS; Lu F; Wang K; Yong KT
Theranostics; 2015; 5(8):818-33. PubMed ID: 26000055
[TBL] [Abstract][Full Text] [Related]
25. Co-Delivery of Doxorubicin and Survivin shRNA-Expressing Plasmid Via Microenvironment-Responsive Dendritic Mesoporous Silica Nanoparticles for Synergistic Cancer Therapy.
Li Z; Zhang L; Tang C; Yin C
Pharm Res; 2017 Dec; 34(12):2829-2841. PubMed ID: 28948461
[TBL] [Abstract][Full Text] [Related]
26. Doxorubicin and siRNA Codelivery via Chitosan-Coated pH-Responsive Mixed Micellar Polyplexes for Enhanced Cancer Therapy in Multidrug-Resistant Tumors.
Butt AM; Amin MC; Katas H; Abdul Murad NA; Jamal R; Kesharwani P
Mol Pharm; 2016 Dec; 13(12):4179-4190. PubMed ID: 27934479
[TBL] [Abstract][Full Text] [Related]
27. Synergistic antitumor effects of combination treatment with metronomic doxorubicin and VEGF-targeting RNAi nanoparticles.
Kwak G; Jo SD; Kim D; Kim H; Kim MG; Kim K; Kwon IC; Kim SH
J Control Release; 2017 Dec; 267():203-213. PubMed ID: 28823674
[TBL] [Abstract][Full Text] [Related]
28. Survivin stable knockdown by siRNA inhibits tumor cell growth and angiogenesis in breast and cervical cancers.
Li QX; Zhao J; Liu JY; Jia LT; Huang HY; Xu YM; Zhang Y; Zhang R; Wang CJ; Yao LB; Chen SY; Yang AG
Cancer Biol Ther; 2006 Jul; 5(7):860-6. PubMed ID: 16861916
[TBL] [Abstract][Full Text] [Related]
29. Effective response of doxorubicin-sensitive and -resistant breast cancer cells to combinational siRNA therapy.
Aliabadi HM; Maranchuk R; Kucharski C; Mahdipoor P; Hugh J; Uludağ H
J Control Release; 2013 Nov; 172(1):219-228. PubMed ID: 23994345
[TBL] [Abstract][Full Text] [Related]
30. Oridonin synergistically enhances the anti-tumor efficacy of doxorubicin against aggressive breast cancer via pro-apoptotic and anti-angiogenic effects.
Li J; Wu Y; Wang D; Zou L; Fu C; Zhang J; Leung GP
Pharmacol Res; 2019 Aug; 146():104313. PubMed ID: 31202781
[TBL] [Abstract][Full Text] [Related]
31. Nano-delivery vehicle based on chlorin E6, photodynamic therapy, doxorubicin chemotherapy provides targeted treatment of HER-2 negative, ανβ3-positive breast cancer.
He Z; Jiang H; Zhang X; Zhang H; Cui Z; Sun L; Li H; Qian J; Ma J; Huang J
Pharmacol Res; 2020 Oct; 160():105184. PubMed ID: 32946931
[TBL] [Abstract][Full Text] [Related]
32. Sequential treatment of drug-resistant tumors with RGD-modified liposomes containing siRNA or doxorubicin.
Jiang J; Yang SJ; Wang JC; Yang LJ; Xu ZZ; Yang T; Liu XY; Zhang Q
Eur J Pharm Biopharm; 2010 Oct; 76(2):170-8. PubMed ID: 20600887
[TBL] [Abstract][Full Text] [Related]
33. Enhanced antitumor efficacy of arginine modified amphiphilic nanoparticles co-delivering doxorubicin and iSur-pDNA via the multiple synergistic effect.
Song Y; Tang C; Yin C
Biomaterials; 2018 Jan; 150():1-13. PubMed ID: 29028548
[TBL] [Abstract][Full Text] [Related]
34. Multifunctional Polymeric Micelles Co-loaded with Anti-Survivin siRNA and Paclitaxel Overcome Drug Resistance in an Animal Model of Ovarian Cancer.
Salzano G; Navarro G; Trivedi MS; De Rosa G; Torchilin VP
Mol Cancer Ther; 2015 Apr; 14(4):1075-84. PubMed ID: 25657335
[TBL] [Abstract][Full Text] [Related]
35. Gambogic acid sensitizes resistant breast cancer cells to doxorubicin through inhibiting P-glycoprotein and suppressing survivin expression.
Wang S; Wang L; Chen M; Wang Y
Chem Biol Interact; 2015 Jun; 235():76-84. PubMed ID: 25824409
[TBL] [Abstract][Full Text] [Related]
36. Survivin silencing as a promising strategy to enhance the sensitivity of cancer cells to chemotherapeutic agents.
Trabulo S; Cardoso AM; Santos-Ferreira T; Cardoso AL; Simões S; Pedroso de Lima MC
Mol Pharm; 2011 Aug; 8(4):1120-31. PubMed ID: 21619051
[TBL] [Abstract][Full Text] [Related]
37. Therapeutic targeting of erbB3 with MM-121/SAR256212 enhances antitumor activity of paclitaxel against erbB2-overexpressing breast cancer.
Wang S; Huang J; Lyu H; Cai B; Yang X; Li F; Tan J; Edgerton SM; Thor AD; Lee CK; Liu B
Breast Cancer Res; 2013; 15(5):R101. PubMed ID: 24168763
[TBL] [Abstract][Full Text] [Related]
38. Improved antitumor activity and reduced toxicity of doxorubicin encapsulated in poly(ε-caprolactone) nanoparticles in lung and breast cancer treatment: An in vitro and in vivo study.
Cabeza L; Ortiz R; Prados J; Delgado ÁV; Martín-Villena MJ; Clares B; Perazzoli G; Entrena JM; Melguizo C; Arias JL
Eur J Pharm Sci; 2017 May; 102():24-34. PubMed ID: 28219748
[TBL] [Abstract][Full Text] [Related]
39. α- Tocopherol succinate loaded nano-structed lipid carriers improves antitumor activity of doxorubicin in breast cancer models in vivo.
Fernandes RS; Silva JO; Seabra HA; Oliveira MS; Carregal VM; Vilela JMC; Andrade MS; Townsend DM; Colletti PM; Leite EA; Cardoso VN; Ferreira LAM; Rubello D; Barros ALB
Biomed Pharmacother; 2018 Jul; 103():1348-1354. PubMed ID: 29864917
[TBL] [Abstract][Full Text] [Related]
40. Indocyanine green/doxorubicin-encapsulated functionalized nanoparticles for effective combination therapy against human MDR breast cancer.
Chen HH; Lu IL; Liu TI; Tsai YC; Chiang WH; Lin SC; Chiu HC
Colloids Surf B Biointerfaces; 2019 May; 177():294-305. PubMed ID: 30771581
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]